Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.

被引：0
|
作者：
Kaufman, Howard L.
Russell, Jeffrey
Hamid, Omid
Bhatia, Shailender
Terheyden, Patrick
D'Angelo, Sandra P.
Shih, Kent C.
Lebbe, Celeste
Linette, Gerald P.
Milella, Michele
Brownell, Isaac
Lewis, Karl D.
Lorch, Jochen H.
von Heydebreck, Anja
Mahnke, Lisa
Nghiem, Paul
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Angeles Clin & Res Inst, Los Angeles, CA USA
[4] Univ Washington, Med Ctr, South Lake Union, Seattle, WA 98195 USA
[5] Univ Lubeck, Lubeck, Germany
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] CHU Paris, GH St Louis Lariboisiere F Widal, Hosp St Louis, Paris, France
[9] Univ Washington, Sch Med, Seattle, WA 98195 USA
[10] Ist Nazl Tumori Regina Elena IRCCS, Rome, Italy
[11] Natl Canc Inst, Bethesda, MD USA
[12] Univ Colorado Denver, Sch Med, Aurora, CO USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Merck KGaA, Darmstadt, Germany
[15] EMD Serono, Billerica, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.80
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
80
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma
    Kratzsch, Dorothea
    Simon, Jan-Christoph
    Poenitzsch, Iris
    Ziemer, Mirjana
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 (01): : 73 - 75
  • [22] CHEMOTHERAPY FOR METASTATIC MERKEL CELL-CARCINOMA
    GEORGE, TK
    DISANTAGNESE, P
    BENNETT, JM
    CANCER, 1985, 56 (05) : 1034 - 1038
  • [23] Electrical Chemotherapy in Metastatic Merkel Cell Carcinoma
    John, G.
    Bouveret, C.
    Kuchenbecker, J.
    Krempien, R.
    Hegenbarth, K.
    Gatzky, E. J.
    Lommel, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 26 - 27
  • [24] Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
    Osai, William E.
    Ng, Chaan S.
    Pagliaro, Lance C.
    ANTI-CANCER DRUGS, 2008, 19 (04) : 427 - 429
  • [25] Ipilimumab plus Nivolumab in Avelumab-refractory Merkel Cell Carcinoma - a retrospective multicenter Analysis
    Glutsch, V.
    Kneitz, H.
    Gesierich, A.
    Goebeler, M.
    Posch, C.
    Haferkamp, S.
    Becker, J. C.
    Ugurel, S.
    Schilling, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 47 - 48
  • [26] Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy
    van Hagen, Tom
    Sandhu, Shahneen
    Nghiem, Paul
    Bhatia, Shailender
    Brohl, Andrew S.
    Hamid, Omid
    Mehnert, Janice M.
    Terheyden, Patrick
    Shih, Kent C.
    Brownell, Isaac
    Lebbe, Celeste
    Lewis, Karl D.
    Linette, Gerald P.
    Milella, Michele
    Hennessy, Meliessa
    Bajars, Marcis
    Hicking, Christine
    D'Angelo, Sandra P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 172 - 173
  • [27] Projecting long term survival for avelumab in refractory Merkel cell carcinoma.
    Phatak, Hemant
    Proskorovsky, Irina
    Lanitis, Tereza
    Ambavane, Apoorva
    Hunger, Matthias
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
    Glutsch, Valerie
    Kneitz, Hermann
    Gesierich, Anja
    Goebeler, Matthias
    Haferkamp, Sebastian
    Becker, Juergen C.
    Ugurel, Selma
    Schilling, Bastian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (07) : 2087 - 2093
  • [29] Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
    Valerie Glutsch
    Hermann Kneitz
    Anja Gesierich
    Matthias Goebeler
    Sebastian Haferkamp
    Jürgen C. Becker
    Selma Ugurel
    Bastian Schilling
    Cancer Immunology, Immunotherapy, 2021, 70 : 2087 - 2093
  • [30] Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
    Bharmal, Murtuza
    Kearney, Mairead
    Zheng, Ying
    Phatak, Hemant
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 349 - 359
12345